Commentary: Sglt2 Inhibitors Reduce Mortality And Heart Failure In Patients With Type 2 Diabetes Mellitus---Is Metabolic Reprogramming The Mechanism For These Favorable Outcomes?
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Harold L. Lazar Source Type: research
More News: Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Heart Failure | SGLT2 Inhibitors